Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma

<i>Background:</i> Immunotherapy has drastically changed the outlook for melanoma patients over the past decade. Specifically, the dual blockade of immune checkpoints using ipilimumab and nivolumab has shown unprecedented response rates and survival outcomes. This immense achievement, th...

Full description

Bibliographic Details
Main Authors: Nethanel Asher, Guy Ben-Betzalel, Shaked Lev-Ari, Ronnie Shapira-Frommer, Yael Steinberg-Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, Gal Markel
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
immunotherapy
programmed cell death 1 receptor
melanoma
CTLA-4 antigen
drug therapy-combination
Online Access:https://www.mdpi.com/2072-6694/12/8/2329

Internet

https://www.mdpi.com/2072-6694/12/8/2329

Similar Items